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INTRODUCTION 
 
Obesity continues to be an expanding health problem in 
both low-, middle- and high-income countries [1–3]. 
Estimates suggest that the global prevalence of obesity 
will reach 18% in men and surpass 21% in women by 
2025 if current trends continue [4]. Individuals with 
excess adiposity, as indicated by measures of body mass 
index (BMI) [5, 6] and waist circumference [7], are at 
higher risk of chronic disease including diabetes and 
cardiovascular disorders. Obesity-induced endoplasmic 
reticulum (ER) stress, which leads to various metabolic 
and immune dysregulation, may link excess adiposity to 
the development of these age-related diseases [8, 9], ER 
stress has also been linked with cellular senescence 
[10], further implying a role for obesity in ageing. 
 
Several observational studies have investigated the 
association between obesity and ageing though 
assessment of telomere length. The telomere refers to 
terminal DNA-protein complexes at the chromosome, 
which primarily functions to maintain chromosomal 
stability [11]. Telomere shortening is regarded a marker 
of biological ageing and has been linked with higher 
risk of cardiovascular disease and death [12, 13]. 
However, the association between obesity and telomere 
length remains elusive. In a recent meta-analysis 
including a total of twelve studies and 8,010 
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ABSTRACT 
 
Obesity may accelerate ageing through chronic inflammation. To further examine this association, we assessed 
current adiposity, adiposity at early adulthood and life course overweight trajectories in relation to leukocyte 
telomere length (LTL). We included a total of 7,008 nationally representative U.S. residents and collected 
information on objectively measured body mass index (BMI), waist circumference and percent body fat. BMI at 
age 25 and overweight trajectories were assessed using self-reported history. Leukocyte telomere length (LTL) 
relative to a standard DNA reference (T/S ratio) was quantified by polymerase chain reaction (PCR). Linear 
regression models were used to examine the difference in LTL across adiposity measures at examination, BMI 
at age 25, and overweight trajectories. A 0.2% decrease in telomere length (95% CI: -0.3 to -0.07%) was 
observed for every kg/m2 increase in BMI, whereas a unit increase in waist circumference (cm) and percent 
body fat contributed to a 0.09% and 0.01% decrease in LTL, respectively. Higher BMI and being obese at age 25 
contributed to lower LTL at older ages. Associations between weight loss through life course and LTL were 
observed, which further marked the importance of life course adiposity dynamics as a determinant of ageing. 
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participants, a 16% lower standardised mean difference 
(SMD) of telomere length was observed cross-
sectionally in obese individuals compared to those with 
normal weight (Summary SMD: 0.84, 95% CI: 0.22–
1.46), but this finding was not statistically significant 
[14]. There was also high heterogeneity among studies 
which was not explained by laboratory methods used to 
assess telomere length. Moreover, most included studies 
used BMI to define obesity, with central obesity only 
measured in two Asian studies [15, 16] and body fat in 
one British study excluding individuals with BMI 30 
kg/m2 or above [17]. There is indication that adiposity 
in earlier age, or its life course trajectories, may impact 
physiological functions in later life as shown with blood 
Table 1. Characteristics of study participants and mean telomere length (LTL). 
 
 N Weighted % Mean LTL (95% CI) 
Age, years     
20–29 1107 17.84 1.21 (1.17-1.24) 
30-39 1182 21.33 1.11 (1.08-1.15) 
40-49 1288 22.15 1.07 (1.04-1.11) 
50-59 975 16.52 0.99 (0.96-1.03) 
60-69 1169 11.00 0.96 (0.92-0.99) 
70-85 1287 11.16 0.87 (0.84-0.90) 
Sex     
Male 3586 49.70 1.05 (1.05-1.08) 
Female 3422 50.30 1.06 (1.03-1.09) 
Race/ethnicity     
Non-Hispanic white 3581 74.02 1.04 (1.01-1.08) 
Non-Hispanic black 1219 9.19 1.11 (1.07-1.15) 
Mexican American 1683 6.89 1.06 (1.02-1.09) 
Other 525 9.90 1.10 (1.04-1.17) 
Education     
Less than high school 2360 21.01 1.02 (0.99-1.05) 
High school 1639 26.24 1.05 (1.01-1.09) 
Higher education 3009 52.75 1.08 (1.05-1.10) 
Smoking status    
Current smokers 3525 49.74 1.07 (1.04-1.11) 
Former smokers 1901 25.46 1.01 (0.98-1.04) 
Never smokers 1582 24.80 1.07 (1.04-1.11) 
Alcohol consumption    
Never 950 11.86 1.06 (1.02-1.11) 
Up to once a week 4677 65.25 1.05 (1.02-1.08) 
2-3 times per week 696 12.07 1.09 (1.06-1.13) 
4 times per week or more 685 10.82 1.04 (1.01-1.07) 
Vigorously active    
No 5867 80.25 1.04 (1.01-1.07) 
Yes 1141 19.75 1.12 (1.09-1.14) 
Cancer diagnosis    
No 6418 92.17 1.06 (1.03-1.09) 
Yes 590 7.83 0.97 (0.93-1.00) 
Diabetes    
No 5978 89.47 1.07 (1.04-1.10) 
Yes 1030 10.53 0.98 (0.95-1.01) 
Hypertension    
No 3965 63.50 1.09 (1.06-1.12) 
Yes 3043 36.50 1.00 (0.97-1.03) 
Hypertriglyceridemia    
No 5782 83.41 1.07 (1.04-1.10) 
Yes 1226 16.59 1.00 (0.96-1.04) 
Low HDL    
No 4458 63.55 1.06 (1.03-1.09) 
Yes 2550 36.45 1.05 (1.02-1.08) 
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pressure [18]. However, little is known regarding any 
impact of adiposity at earlier age or changes of 
adiposity over time on telomere length at later life, 
especially in the general population. 
 
To gain further insight into the role of obesity in ageing, 
we characterised the association between adiposity 
measures including BMI, waist circumference and body 
fat, and telomere length in the 1999-2002 U.S. National 
Health and Nutrition Examination Survey (NHANES). 
Furthermore, we additionally assessed telomere length 
using self-reported information on BMI at age 25 
among those 30 years and older. An understanding of 
the lifetime relationships between obesity and telomere 
length may help guide public health efforts to reduce 
levels of obesity and its adverse health outcomes. 
 
RESULTS 
 
Weighted characteristics of study participants and 
corresponding mean relative telomere length are shown 
in Table 1. Telomere length (LTL) decreased with older 
Table 2. Associations between current adiposity measures and log-transformed leukocyte telomere length 
(LTL). 
 
 N  
Weighted 
% 
Mean 
LTL 
(SE) 
Log LTL difference1 Log LTL difference2 Log LTL difference2,3 
β 95% CI β 95% CI β 95% CI 
BMI, kg/m2          
Continuous    -0.002 -0.004, -
0.0007 
-0.002 -0.003, -
0.0006 
-0.002 -0.003, -
0.0007 
Clinical cut-off          
<18.5 104 17.54 1.07 
(0.03) 
-0.04 -0.08, 
0.005 
-0.03 -0.07, 0.01 -0.03 -0.07, 0.01 
18.5-25 2137 33.07 1.09 
(0.02) 
Reference  Reference  Reference  
25-30 2556 35.09 1.04 
(0.02) 
-0.02 -0.04, 
0.002 
-0.02 -0.04, 
0.002 
-0.02 -0.04, 
0.004 
≥30 2211 30.08 1.03 
(0.02) 
-0.04 -0.06, -
0.01 
-0.03 -0.05, -
0.009 
-0.03 -0.05, -0.01 
Waist 
circumference4 
         
Continuous    -0.001 -0.002, -
0.0004 
-0.0008 -0.001, -
0.0003 
-0.0009 -0.001, -
0.0003 
Clinical cut-off          
Normal 3437 52.11 1.09 
(0.02) 
Reference  Reference  Reference  
High 3571 47.89 1.02 
(0.02) 
-0.03 -0.05, -
0.009 
-0.02 -0.04, -
0.006 
-0.02 -0.04, -
0.006 
Percent body 
fat5 
         
Continuous    -0.002 -0.003, -
0.0004 
-0.002 -0.003, -
0.0003 
-0.001 -0.003, -
0.00005 
Clinical cut-off          
Normal 1122 40.46 1.16 
(0.02) 
Reference  Reference  Reference  
High 1746 59.54 1.11 
(0.02) 
-0.03 -0.05, -
0.01 
-0.03 -0.05, -
0.009 
-0.02 -0.04, -
0.005 
1Adjusted for age at LTL measurement (continuous), sex, and race/ethnicity 
2Adjusted for age at LTL measurement (continuous), sex, race/ethnicity, education, smoking status, alcohol intake, vigorous 
physical activity 
3Additional adjustment for diabetes, hypertension, hypertriglyceridemia, low HDL, and self-reported cancer diagnosis 
4Normal: ≤102 cm (men) and ≤88 cm (women); high: >102 cm (men) and >88 cm (women) 
5Measured in 2,868 individuals aged 20-49 years. Normal: ≤25% (men) and ≤35% (women); high: >25% (men) and >35% 
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age, shortest among non-Hispanic whites and those who 
did not finish high school. The mean BMI measured at 
examination in men and women were 27.8 ± 0.14 and 
28.1 ± 0.20 kg/m2, respectively, and the mean self-
reported BMI was 27.7 ± 0.15 and 27.3 ± 0.18 kg/m2 
for men and women, respectively. Over 65% of the 
participants had measured BMI of 25 kg/m2 or greater, 
and around 46% of them were obese. Nearly 48% of 
participants had excess waist circumference, and 59% 
of participants had excess body fat. 
 
Associations between current adiposity and telomere 
length 
 
When assessing objectively measured adiposity and 
LTL at current age, we found shorter LTL with higher 
measured BMI, waist circumference, and percent body 
fat. In the fully adjusted model, a 0.2% decrease in 
telomere length (95% CI: -0.3 to -0.06%) was observed 
for every increase in BMI, and a unit increase in waist 
circumference and percent body fat contributed to a 
0.08% (95% CI: -0.1 to -0.03%) and 0.2% (-0.3 to -
0.03%) decrease in LTL, respectively. Trends with 
adiposity categories were similar. Being obese (BMI 30 
kg/m2 or greater) was associated with a 3% (95% CI: -5 
to -0.9%) decrease in LTL compared to those with BMI 
18.5-25 kg/m2. With the dichotomous overweight status 
(</≥25 kg/m2), we found that being overweight was 
associated with a 3% decrease in LTL (95% CI: -4 to -
0.3%). Estimates were similar for excess adiposity by 
waist circumference and percent body fat (Table 2). 
Results did not markedly alter after we adjusted for 
presence of other metabolic disorders and cancer 
diagnosis.  
 
Quantile regression analysis 
 
We further performed quantile regression analyses to 
characterise the association between adiposity measures 
and LTL. This analysis provided information on 
changes in extreme quantiles and outliers of LTL for 
every unit increase in adiposity indices. Changes in 
LTL with increasing adiposity varied across LTL 
 
Figure 1. Difference in mean log-transformed LTL (T/S ratio) across quantiles of LTL for every unit increase in 
body mass index (BMI), waist circumference (WC), and percent body fat (%BF). All models were adjusted for age 
at LTL measurement (continuous), sex, race/ethnicity, education, smoking status, alcohol intake, and vigorous physical 
activity. 
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Table 3. Associations between self-reported BMI and log-transformed leukocyte 
telomere length (LTL). All models were adjusted for age at LTL measurement (continuous), sex, 
race/ethnicity, education, smoking status, alcohol intake, and vigorous physical activity. 
 
Age at 
examination 
N (%) Log LTL difference Log LTL difference1 
β 95% CI β 95% CI 
Current BMI, kg/m2     
All ages      
Continuous  -0.002 -0.003, -0.0003 -0.003 -0.004, -0.0003 
Clinical cut-off      
<18.5 90 (1.51) -0.06 -0.12, 0.002 -0.005 -0.10, 0.09 
18.5-25 2283 (35.96) Reference  Reference  
25-30 2540 (35.86) -0.03 -0.04, -0.01 -0.02 -0.04, -0.0003 
≥30  -0.04 -0.06, -0.02 -0.03 -0.06, -0.01 
BMI at age 25, kg/m2     
All ages2      
Continuous  -0.002 -0.004, -0.0004 -0.002 -0.004, -0.0004 
Clinical cut-off      
<18.5 104 (1.75) 0.007 -0.02, 0.03 0.02 -0.02, 0.05 
18.5-25 2137 (33.07) Reference  Reference  
25-30 2556 (35.09) -0.008 -0.03, 0.01 -0.004 -0.03, 0.02 
≥30 2211 (30.08) -0.03 -0.06, 0.001 -0.02 -0.05, 0.008 
Annual change3  -0.02 -0.03, -0.004 -0.02 -0.03, -0.005 
Age 30-39      
Continuous  -0.005 -0.008, -0.003 -0.005 -0.008, -0.003 
Clinical cut-off      
<18.5 60 (5.23) 0.04 -0.03, 0.06 0.04 -0.03, 0.11 
18.5-25 676 (60.28) Reference  Reference  
25-30 299 (23.95) -0.02 -0.08, -0.003 -0.02 -0.06, 0.02 
≥30 122 (10.54) -0.05 -0.11, -0.04 -0.05 -0.09, -0.02 
Annual change3  -0.003 -0.03, 0.02 -0.005 -0.03, 0.02 
Age 40-49      
Continuous  -0.002 -0.007, 0.002 -0.002 -0.007, 0.002 
Clinical cut-off      
<18.5 75 (5.96) -0.02 -0.08, 0.04 -0.03 -0.13, 0.05 
18.5-25 780 (63.63) Reference  Reference  
25-30 298 (23.54) -0.02 -0.06, 0.03 -0.01 -0.06, 0.04 
≥30 99 (6.87) -0.03 -0.08, 0.04 -0.01 -0.08, 0.05 
Annual change3  -0.08 -0.18, 0.007 -0.08 -0.19, 0.004 
Age 50-59      
Continuous  0.002 -0.001, 0.005 0.002 -0.001, 0.005 
Clinical cut-off      
<18.5 79 (8.52) -0.001 -0.06, 0.06 0.03 -0.05, 0.13 
18.5-25 628 (66.89) Reference  Reference  
25-30 193 (20.13) 0.04 -0.001, 0.08 0.02 -0.02, 0.06 
≥30 51 (4.46) 0.02 -0.04, 0.09 0.02 -0.03, 0.08 
Annual change3 0.20 (0.006) -0.07 -0.14, -0.008 -0.07 -0.15, -0.007 
Age 60-69      
Continuous  -0.001 -0.005, 0.002 -0.001 -0.005, 0.002 
Clinical cut-off      
<18.5 77 (7.03) 0.02 -0.02, 0.08 -0.006 -0.11, 0.10 
18.5-25 775 (70.31) Reference  Reference  
25-30 219 (19.05) 0.02 -0.02, 0.06 0.007 -0.03, 0.05 
≥30 48 (4.46) -0.04 -0.12, 0.04 -0.03 -0.11, 0.04 
Annual change3  0.007 -0.10, 0.11 0.006 -0.10, 0.11 
Age 70-85      
Continuous  0.002 -0.006, 0.01 0.002 -0.006, 0.01 
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Clinical cut-off      
<18.5 98 (9.61) 0.03 -0.04, 0.09 0.04 -0.05, 0.14 
18.5-25 887 (76.07) Reference  Reference  
25-30 186 (12.12) 0.04 -0.009, 0.08 0.04 -0.008, 0.08 
≥30 32 (2.20) 0.04 -0.11, 0.19 0.03 -0.10, 0.15 
Annual change3  -0.08 -0.27, 0.11 -0.08 -0.28, 0.11 
1Predicted BMI from the two-step regression approach on self-reported history of current BMI 
2Additionally adjusted for interval in years between age 25 and age at examination 
3Difference between self-reported BMI at age 25 years and BMI measured at examination divided 
by interval time in years 
 
quantiles as shown in Figure 1. However, no 
statistically significant difference across quantiles 
overall were found with Wald test (P=0.15, 0.45 and 
0.62 for BMI, waist circumference and percent body fat, 
respectively). Associations  with the  median (50th 
quantile) of LTL were similar to those observed using 
the linear regression approach, with 0.2%, 0.08% and 
0.01% decreases in LTL with every unit increase in 
BMI, waist circumference and percent body fat, 
respectively 
 
Self-reported adiposity in relation to current 
telomere length 
 
We further assessed adiposity history using self-
reported BMI and LTL. Table 3 showed associations 
between self-reported BMI at current age and at age 25 
with LTL at current age. Associations between self-
reported current BMI and LTL were similar to those 
observed with objectively measured BMI. In age-
stratified analyses, a 0.5% decrease in LTL was 
observed among those aged 30-40 for every unit 
increase in BMI at age 25 years. A similar association 
was seen between being obese at 25 years and LTL at 
age 30-40. Among those aged 50-60, a 7% decrease in 
LTL was seen with higher annual change in BMI since 
aged 25 years. A test for interaction suggested a 
statistically significant interaction between BMI at age 
25 and age group (Pinteraction=0.004). Associations were 
similar when we used the estimation of measured BMI 
at age 25 from regressing current measured over self-
reported BMI (Table 3).  
 
Associations between overweight trajectories and 
telomere length 
 
Finally, we estimated LTL differences across life course 
trajectories based on overweight status at 25 years and 
at examination. Compared to those who had BMI <25 
kg/m2 at age 25 and at examination, shorter LTL was 
observed among individuals aged 30-40 years who were 
overweight at age 25 regardless of current overweight 
status (Table 4). LTL was shorter among those who 
were overweight at age 40-50, regardless of overweight 
status at age 25. Interestingly, a 12% increase in LTL (1 
to 24%) was observed among those who were 
overweight at age 25 and had normal weight at age 50-
60 years. No association was found among those aged 
60 and over. A significant interaction was found 
between overweight trajectory and current age 
(Pinteraction=0.0007). 
 
DISCUSSION 
 
We found decreased LTL with increasing BMI, waist 
circumference and percent body fat, and among those 
with excess adiposity compared to those without. 
Higher BMI and being obese at age 25 was associated 
with lower LTL at age 30-40. Among those who were 
overweight at age 25, LTL decreased among those who 
became non-overweight at age 30-40, and increased 
among those who were non-overweight at age 50-60, 
compared to those who were non-overweight both at 
age 25 and at current age.  
 
Excess adiposity may lead to telomere shortening 
through inflammation and generation of oxidative stress 
[19]. As an endocrine organ [20], adipose tissue may 
promote inflammation through directly secreting pro-
inflammatory mediators and through increased levels of 
adipokines, particularly leptin [21]. Pro-inflammatory 
properties of leptin have been shown [21], with binding 
to its receptor leading to activation of signalling 
pathways involved in chronic inflammation and age-
related diseases such as JAK/STAT and NF-κB [22]. 
Corroborating a role of obesity in ageing, we found 
further evidence linking excess adiposity and shorter 
telomere length which echoed some previous findings 
[15, 23–26]. Despite the suggested association, a 
Mendelian randomisation analysis comprising Danish 
populations found no evidence of a causal association 
between BMI and telomere length [24]. Insufficient 
sample size and mediation of the effect by inflammation 
as shown by genetically-determined C-reactive protein 
were argued to have explained this null association [24]. 
Additionally, many studies assessed adiposity and LTL 
in a linear fashion [14, 27]. In a systematic analysis of 
environmental exposures and LTL in the NHANES, 
linear associations between BMI, waist circumference 
and body fat were also noted although only trunk fat 
 www.aging-us.com 7 AGING (Albany NY) 
Table 4. Associations between overweight trajectories and telomere length, stratified by age at examination. 
 
Age at examination N (%) Mean BMI (SE) Mean 
LTL(SE) 
Log LTL difference1  
At age 25  At 
examination 
β 95% CI 
Age 30-39       
Non-overweight/non-overweight 393 (36.07) 20.81 (0.11) 22.14 (0.10) 1.13 (0.02) Ref  
Non-overweight /overweight 368 (29.97) 22.44 (0.12) 28.97 (0.21) 1.13 (0.02) -0.009 -0.04, 0.02 
Overweight/non-overweight 26 (2.16) 27.09 (0.31) 23.52 (0.25) 0.99 (0.03) -0.12 -0.20, -0.05 
Overweight/overweight 395 (31.80) 29.53 (0.23) 33.69 (0.39) 0.99 (0.04) -0.13 -0.19, -0.02 
Age 40-49       
Non-overweight/non-overweight 320 (28.46) 20.59 (0.12) 22.10 (0.12) 1.12 (0.02) Ref  
Non-overweight /overweight 571 (41.46) 21.88 (0.10) 29.45 (0.24) 1.05 (0.02) -0.06 -0.11, -0.02 
Overweight/non-overweight 37 (3.58) 27.09 (0.31) 23.29 (0.31) 1.13 (0.05) 0.006 -0.08, 0.09 
Overweight/overweight 360 (26.50) 28.83 (0.36) 34.30 (0.58) 1.05 (0.03) -0.07 -0.13, -0.009 
Age 50-59       
Non-overweight/non-overweight 239 (26.75) 20.28 (0.13) 22.46 (0.13) 0.99 (0.02) Ref  
Non-overweight /overweight 492 (49.13) 21.97 (0.13) 29.45 (0.24) 0.98 (0.02) -0.005 -0.05, 0.04 
Overweight/non-overweight 19 (1.49) 27.12 (0.61) 23.44 (0.42) 1.14 (0.07) 0.12 0.01, 0.24 
Overweight/overweight 225 (22.63) 28.52 (0.32) 33.79 (0.69) 1.01 (0.02) 0.03 -0.03, 0.08 
Age 60-69       
Non-overweight/non-overweight 253 (23.86) 20.52 (0.14) 22.54 (0.14) 0.96 (0.02) Ref  
Non-overweight /overweight 649 (54.02) 21.44 (0.09) 30.33 (0.25) 0.96 (0.02) -0.01 -0.06, 0.03 
Overweight/non-overweight 16 (1.01) 26.25 (0.37) 23.35 (0.50) 0.89 (0.07) -0.05 -0.22, 0.10 
Overweight/overweight 251 (21.11) 27.66 (0.23) 33.16 (0.38) 0.96 (0.02) 0.001 -0.05, 0.06 
Age 70-85       
Non-overweight/non-overweight 393 (32.49) 20.64 (0.12) 22.23 (0.15) 0.87 (0.02) Ref  
Non-overweight /overweight 676 (53.88) 21.24 (0.08) 29.64 (0.18) 0.86 (0.01) -0.009 -0.04, 0.03 
Overweight/non-overweight 39 (2.15) 28.05 (0.60) 22.93 (0.41) 0.87 (0.05) 0.02 -0.10, 0.13 
Overweight/overweight 179 (11.48) 27.57 (0.20) 30.80 (0.37) 0.88 (0.03) 0.03 -0.04, 0.10 
Note: Trajectories reflect overweight status at age 25, followed by that at current age, e.g. non-overweight/overweight refers 
to non-overweight at age 25 and overweight at current age. 
1All models were adjusted for sex, race/ethnicity, education, smoking status, alcohol intake, and vigorous physical activity. 
 
 
remained significant after adjustment for multiple 
comparison [27]. Additionally, associations with 
adiposity history were not examined in the above study. 
Given nonlinear associations between BMI and health 
outcomes such as mortality [28], the use of clinically 
meaningful categories of adiposity may be more useful 
for translation to clinical and public health measures.  
 
In addition to their cross-sectional association, the 
longitudinal correlation between adiposity and telomere 
length is a subject of controversy. A standard deviation 
increase in waist circumference over 6 years was linked 
to a 40 base pair decrease in LTL during the same 
period in a Dutch study [29]. Nevertheless, a Danish 
study including over 4,500 Caucasians and a cohort 
comprising older German populations showed a lack of 
association between weight change and LTL attrition 
between two measurements 10-year and 8-year apart, 
respectively [30, 31]. There is also a lack of 
understanding regarding any critical or sensitive periods 
in which adiposity affects telomere length in later life. 
In the Health and Retirement Study, a positive 
association was shown between being overweight or 
obese in the past 16 years and current telomere length 
among middle-aged and older adults [32]. In our study, 
however, we found associations between BMI at early 
adulthood and current telomere length were limited to 
those younger than 60. These discrepancies further 
indicate the importance of understanding the dynamics 
between adiposity and biological ageing throughout 
lifespan and whether such association affects age-
related diseases.  
 
Differing impacts of weight loss were indicated by 
longer LTL among currently non-overweight 
individuals aged 50-60 who used to be overweight at 
age 25 compared to those who stayed non-overweight at 
both time points, and an opposing association for 
individuals currently aged 30-40. Corroborating the 
former, restored telomere length among overweight and 
obese individuals has been suggested following specific 
weight loss interventions, including bariatric surgery 
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[33] and bioenteric intragastric balloon (BIB) in adults 
[34], and lifestyle modification in adolescents [35]. 
Nevertheless, a positive association between weight loss 
and LTL was observed among BIB but not bariatric 
surgery patients [33, 34, 36] and no alteration of 
telomere length was observed following lifestyle 
modification in adults [37, 38]. Except one study which 
followed the participants until 10 years after undergoing 
bariatric surgery [33], these previous findings had 
relatively short-term follow-up (6 months to 4.5 years), 
which may have limited the sensitivity in observing 
changes secondary to weight loss. Additionally, our 
varying results in different age groups may support 
varying roles of stages at which weight loss takes place 
as indicated by discrepancies of prior findings among 
adolescents and adults [35]. Alternatively, the weaker 
associations we observed between overweight 
trajectories in older age groups may imply that any 
effect of adiposity on telomere length is less apparent 
with longer intervals. Considering these potential 
explanations, further clarification regarding the impact 
of life course adiposity on ageing is necessary. 
 
The strength of this study lies on the nationally 
representative sample included in the NHANES 
surveys. We were able to assess different measures of 
adiposity and take into account potential confounders 
and co-morbid metabolic disorders. Spurious 
correlations may be of concern when performing 
multiple comparisons as shown in our study. However, 
we planned our analyses based on prior evidence and 
our results are explicable by suggested biological 
pathways and findings from other studies [39]. 
Therefore the observed association is unlikely to be 
spurious. One of the limitations of this study is that 
information was based on cross-sectional assessments. 
Whilst we were able to evaluate past BMI history and 
assess trajectories of overweight, our findings only 
implied association rather than causation. Recall bias 
may lead to misclassification when using self-reported 
data. However, we predicted BMI at age 25 by taking 
into account discrepancy between current measured and 
self-reported BMI, and found similar results. Another 
limitation is that telomere length may be altered in 
carcinogenesis [40]. Although our findings were robust 
when adjusted for history of cancer, residual 
confounding may have occurred due to lack of 
information on cancer incidence.  
 
In summary, our cross-sectional analysis revealed that 
excess adiposity corresponds to shorter telomeres. 
Weight loss among overweight individuals during early 
adulthood may be associated with short-term telomere 
shortening, and longer-term telomere elongation. Our 
findings provide the first indication that the relationship 
between obesity and telomere length changes over an 
individual’s life course. Studies using objective 
measures of obesity should be conducted to confirm our 
conclusions.  
 
MATERIALS AND METHODS 
 
Study population 
 
The National Health and Nutrition Examination Survey 
(NHANES) is a cross-sectional health survey conducted 
by the National Center for Health Statistics (NCHS) in 
representative samples of the non-institutionalized U.S. 
population [41]. The NCHS Institutional Review Board 
(IRB) approved the study and informed consent was 
obtained from participants. Participants were selected 
through a multistage stratified, clustered probability 
sampling. The survey included an interview conducted 
at home and an extensive physical examination, which 
included a blood sample taken in a mobile examination 
center (MEC). This study was based on the continuous 
NHANES 1999-2002, which included 21,004 
participants of all ages. From this population, we 
selected men and women aged 20 years and older who 
had measurements of BMI and waist circumference 
(N=8,889). Pregnant women, determined by a positive 
urine pregnancy test and/or self-reported at the MEC, 
were excluded (N=547). Among the remaining 
participants, a total of 7,027 individuals had 
measurements of leukocyte telomere length. We further 
excluded those with missing values for other covariates: 
education level, smoking status, alcohol consumption, 
and physical activity (N=19). Age and race/ethnicity 
distribution did not differ between those with missing 
values and the final study population with complete data 
(N=7,008). 
 
Telomere length assay 
 
DNA was extracted from whole blood and stored at -
80°C. The telomere length assay was performed in the 
laboratory of Dr. Elizabeth Blackburn at the University 
of California, San Francisco, using the quantitative 
polymerase chain reaction (PCR) method to measure 
telomere length relative to standard reference DNA (T/S 
ratio), as described in detail elsewhere [42, 43]. Each 
sample was assayed 3 times on 3 different days. The 
samples were assayed on duplicate wells, resulting in 6 
data points. Sample plates were assayed in groups of 3 
plates, and no 2 plates were grouped together more than 
once. Assay runs with 8 or more invalid control wells 
were excluded from further analysis (<1% of runs). 
Control DNA values were used to normalize between-
run variability. Runs with more than 4 control DNA 
values falling outside 2.5 standard deviations from the 
mean for all assay runs were excluded from further 
analysis (<6% of runs). For each sample, any potential 
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outliers were identified and excluded from the 
calculations (<2% of samples). The mean and standard 
deviation of the T/S ratio were then calculated 
normally. The inter-assay coefficient of variation was 
6.5%. A logarithmic transformation of T/S ratio was 
performed due to its skewed distribution. 
 
Adiposity assessment 
 
All body measurements were performed using 
standardized methods and equipment [41]. Current body 
mass index (BMI) was calculated from measured 
weight and height. Weight was measured with an 
electronic weight scale in pounds and automatically 
converted to kilograms. Participants only wore 
underwear, disposable paper gowns and foam rubber 
slippers. Standing height was measured with a fixed 
stadiometer to the nearest 1 mm. Waist circumference 
was measured at the high point of the iliac crest at 
minimal respiration using a steel measuring tape to the 
nearest 1 mm [41]. Fat mass was determined through a 
whole body DXA scans with a Hologic QDR-4500A 
fan-beam densitometer (Hologic, Inc., Bedford, 
Massachusetts). Hologic software version 8.26:a3* was 
used. The densitometer scanned participants with an x-
ray source using fan-beam scan geometry while the 
participants were positioned supine on the tabletop. 
Percent body fat was calculated by dividing total fat 
mass by total DXA mass (fat mass and fat-free mass) 
and multiplying by 100. 
 
BMI was also divided into four categories (<18.5, 18.5-
25, 25-30, and ≥30 kg/m2)  according to the National 
Health Institute (NIH) guidelines and dichotomously 
into non-overweight and overweight using 25 kg/m2 as 
a cut-off point [44]. Excess abdominal obesity was 
defined as waist circumference >102 cm in men and 
>88 cm in women based on guidelines published by 
international organizations including the experts in the 
Adult Treatment Panel (ATP) under the National 
Cholesterol Education Program (NCEP) [45]. 
According to the World Health Organization (WHO) 
guidelines, [46] percent body fat ≥25 in men and ≥35 
women were defined as having excess body fat. Self-
reported weight and height at 25 years was collected for 
those aged 30 years and older and BMI at age 25 was 
calculated. The difference between in BMI between 25 
and the age at survey measurement was calculated and 
divided by the number of years between the two time 
points to produce the annual change in BMI. 
 
Assessment of potential confounders 
 
Several demographics and lifestyle factors were 
considered as potential confounders. Age was assesses 
as a continuous variable in the initial analysis and 
subsequently grouped into 20-29, 30-39, 40-49, 50-59, 
60-69, and 70-85 years. Race/ethnicity was categorised 
into Non-Hispanic white, Non-Hispanic black, 
Mexican-American, and other. We classified 
educational attainment as less than high school, high 
school equivalent, and higher than high school. This 
information provided a proxy of socio-economic status 
which has been reported to impact ageing-related 
outcomes [47, 48]. We defined current smokers as those 
who had reported a history of smoking at least 100 
cigarettes during their lifetime and, at the time of the 
interview, reported smoking either every day or some 
days. Former smokers were those who reported 
smoking at least 100 cigarettes during their lifetime but 
currently did not smoke. Never smokers were those who 
had not smoked 100 cigarettes during their lifetime. 
Vigorous physical activity (yes, no) was described as 
reporting 3 or more physical activities of at least 6 
metabolic equivalents (METs) per week, each with 
duration of at least 10 minutes [49]. Frequency of 
alcohol consumption was collected during interview and 
categorized into never (had less than 12 alcohol drinks 
in the entire life), up to once a week, 2-3 times a week, 
and 4 times a week or more. A self-reported history of 
cancer diagnosis (yes, no) was based on a positive 
response to the question “Have you ever been told by a 
doctor or other health care professional that you had 
cancer or a malignancy of any kind”. 
 
In addition to demographics and lifestyle, other 
metabolic disorders were taken into account given their 
associations to obesity and age-related disease such as 
cardiovascular disease. The ATP-III definition of 
metabolic syndrome apart from obesity was used to 
define presence of other metabolic disorders (yes, no) 
[45]. Hypertension was defined by blood pressure of 
≥130/≥85 mmHg or any use of antihypertensive drugs. 
Diabetes was defined as fasting glucose ≥110 mg/dL 
(5.55 mmol/L) or any use of insulin or glucose-lowering 
drugs. Any HDL-cholesterol levels <40 mg/dL 
(1.04 mmol/L) for men or <50 mg/dL for women 
(1.29 mmol/L) were considered as low. Triglyceridemia 
was defined as any levels of fasting triglycerides ≥150 
mg/dL (1.69 mmol/L). Blood pressure was measured 
with mercury manometer and the average of the second 
and third blood pressure measurements was taken. 
Plasma glucose levels were measured by using a 
hexokinase method. Blood lipids were measured 
enzymatically [41]. 
 
Statistical analysis 
 
Survey-weighted linear regression was performed to 
assess differences in log-transformed T/S ratio by 
different levels of current adiposity measures, using the 
weights specific for the genetic subsample [41, 42]. The 
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percentage change in LTL was estimated by multiplying 
the parameter estimate by 100 [42]. First, we used 
models adjusted for age as a continuous variable, sex 
and race/ethnicity to assess any difference in log-
transformed LTL by current measured BMI, waist 
circumference, and percent body fat as continuous 
variables. A similar analysis was performed using the 
four categories of BMI and dichotomous categories of 
waist circumference and percent body fat. Additionally, 
we also assessed overweight status by BMI as a 
dichotomous variable (</≥25 kg/m2). The final models 
were further adjusted for variables which have been 
linked with both adiposity and ageing-related outcomes 
including education, smoking status, alcohol intake, and 
vigorous physical activity. To additionally check if this 
association was affected by metabolic disorders and 
cancer, we adjusted the model for presence of other 
metabolic disorders and cancer diagnosis. 
 
To further characterise the cross-sectional associations 
between adiposity and telomere length, we used fully 
adjusted quantile regression models assessing difference 
in quantiles of LTL with increasing BMI, waist 
circumference, and percent body fat. This analysis 
predicted changes in a given quantile, e.g. the 90th 
quantile of outcome variables instead of their mean, 
allowing a more comprehensive view of the relationship 
between predictors and outcomes [50, 51]. Wald test 
was used to test equality of coefficients across quantiles 
[52]. 
 
We estimated the associations between self-reported 
BMI at age 25 and LTL at examination for those aged 
30 and older. Participant age at examination varied in 
the NHANES. Therefore, we adjusted our models for 
current age in the analysis and we further stratified our 
analysis by age group. Finally, to further examine the 
impact of adiposity changes over the life course on 
biological ageing, we created four indicators of 
adiposity trajectories based on the combination between 
overweight status at age 25 and at examination based on 
the dichotomous BMI cut-off (non-overweight: <25 
kg/m2 and overweight: ≥25 kg/m2). Difference in LTL 
across different trajectories (non-overweight/non-
overweight, non-overweight/overweight, overweight 
/non-overweight, and overweight/overweight) was 
estimated in regression models treating those who had 
normal weight both at age 25 and at examination (non-
overweight/non-overweight) as the referent category. A 
test for interaction was performed by incorporating the 
product term between BMI at age 25 or overweight 
trajectories and age categories. 
 
Because BMI at age 25 was only available from self-
reported data, we performed a sensitivity analysis 
addressing the discrepancy between self-reported and 
measured BMI. First, we took the estimate or regression 
coefficient from a linear model regressing measured 
BMI over self-reported BMI at current age, which was 
regarded to reflect the difference between objectively 
measured and self-reported BMI. This estimate was 
multiplied by self-reported BMI at age 25 as an 
estimation of objectively measured BMI at age 25. We 
subsequently assess LTL based on the predicted BMI at 
age 25.  
 
The NHANES data was prepared with Statistical 
Analysis Software (SAS) release 9.3 (SAS Institute, 
Cary, NC) and survey-weighted analyses were 
performed with the survey package of R version 3.1.2 
(R Foundation for Statistical Computing, Vienna, 
Austria). The R quantreg package incorporating 
sampling weight replicates were used to obtain quantile 
regression estimates, with ninety-five percent 
confidence intervals (95% CI) obtained using 100 
bootstrap re-samples. 
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